These side-effects could be eliminated if genes that counteract seizures could be introduced into the brain. Professor Merab Kokaia at Lund University in Sweden has obtained promising results in animal experiments.
Epilepsy is a fairly common condition, affecting around 1 in every 100 people in Sweden. It increases the risk of depression, sudden death, injury and disability. Today’s medication not only has side-effects, it is also not sufficiently effective. A large proportion of epilepsy patients are not helped by the drugs and cannot be treated with brain surgery either.
Research in recent years has shown that the brain tries to counteract seizures. One of the ways it does this is by increasing levels of a protein-like molecule called neuropeptide Y and the expression of certain receptors for it.
Both Merab Kokaia’s research group and others have previously shown that gene therapy can increase levels of neuropeptide Y in the brain. The Lund researchers are now also the first group in the world to introduce genes that increase the expression of certain receptors for neuropeptides in the brain.
“Neuropeptide Y affects many receptors on the cells in the brain. Some of these increase the risk of seizures and thus have the opposite effect to that which we want to achieve. Therefore it is not ideal to only aim for high levels of neuropeptide Y; we should also ensure that the neuropeptide activates the right receptors”, says Merab Kokaia.He has tested the combined neuropeptide and receptor gene therapy on a rat model of epilepsy and found that the seizures were strongly suppressed. The results have recently been published in the prestigious journal BRAIN.
The genes were introduced into the animals’ brains via harmless viruses. These were injected into the specific parts of the brain that are affected by an epileptic condition.
“If the method works on humans, a single treatment would be sufficient, rather than lifelong medication. Unlike current AEDs, such treatment would also only affect the parts of the brain concerned”, explains Merab Kokaia.
In the USA the Food and Drug Administration (FDA) is now considering an application to test gene therapy for epilepsy on humans. However, this application only concerns introducing genes to increase expression of neuropeptide Y, whereas the Lund group’s findings indicate that genes that increase the expression of the right receptors would be at least as important.
The article is entitled ‘Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures’ and is available at http://brain.oxfordjournals.org/ (enter ‘Kokaia’ in the search box).
Merab Kokaia can be contacted by telephone, +46 46 222 05 47, mobile +46 706 620899, or by email, email@example.com
The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences
Transforming plant cells from generalists to specialists
07.12.2016 | Duke University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine